Skip to main content
  • Sign in
    Welcome !
    My account
    Logout

Stemline Therapeutics, Inc. (STML) Stock Forecast 2025 - AI Price Prediction & Analysis

Stemline Therapeutics, Inc. (STML) AI Stock Price Forecast & Investment Analysis

Stemline Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading Stemline Therapeutics, Inc. interactive price chart and technical analysis...

Stemline Therapeutics, Inc. (STML) - Comprehensive Stock Analysis & Investment Research

Deep dive into Stemline Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Stemline Therapeutics, Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Stemline Therapeutics, Inc.: Stemline Therapeutics, Inc. operates in the Health Technology sector, making it an emerging small-cap investment.

Stemline Therapeutics, Inc. (Stock Symbol: STML) is a leading company in the Health Technology sector , specifically operating within the Biotechnology industry.

The organization employs approximately 100 professionals worldwide and operates under the strategic leadership of CEO Ivan Bergstein.

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Stemline Therapeutics, Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Stemline Therapeutics, Inc.: With $47M in annual revenue and -150.3% net margin, the company demonstrates developing profitability.

Annual Revenue: $47 million generating a -150.3% net profit margin .

Market Capitalization: $532 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -55.1% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Stemline Therapeutics, Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Stemline Therapeutics, Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Stemline Therapeutics, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Stemline Therapeutics, Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Stemline Therapeutics, Inc.: Market positioning analysis based on available financial and operational metrics.

Stemline Therapeutics, Inc. strategically competes in the highly dynamic Biotechnology marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company maintains a healthy 88.4% gross margin, indicating strong pricing power and operational efficiency.

Stemline Therapeutics, Inc. (STML) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Stemline Therapeutics, Inc. stock analysis.

Loading Stemline Therapeutics, Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into Stemline Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Stemline Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Stemline Therapeutics, Inc.: With a P/E ratio of -7.63, the market sees the stock as potentially undervalued.

P/E Ratio -7.63x
P/B Ratio 4.21x
Market Cap $532M
EPS $-1.55
Book Value/Share $2.81
Revenue/Share $1.04
FCF/Share $-2.00
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Stemline Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Stemline Therapeutics, Inc.: An ROE of -55.1% indicates room for improvement in shareholder value creation.

ROE -55.1%
ROA -46.1%
ROIC -55.9%
Gross Margin 88.4%
Operating Margin -155.5%
Net Margin -150.3%
EBT Margin -150.2%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Stemline Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Stemline Therapeutics, Inc.: A current ratio of 7.43 indicates strong liquidity.

Current Ratio 7.43x
Quick Ratio 7.20x
D/E Ratio 0.49x
Financial Leverage 1.16x
Interest Coverage -45.8x
Working Capital $162M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Stemline Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Stemline Therapeutics, Inc.: Free cash flow of $-59M indicates cash challenges that need attention.

Operating Cash Flow $-59M
Free Cash Flow $-59M
FCF/Sales -126.1%
CapEx/Sales 0.0%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Stemline Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Stemline Therapeutics, Inc.: An asset turnover of 0.31x suggests room for improvement in asset utilization.

Asset Turnover 0.31x
Receivables Turnover 5.4x
Inventory Turnover 4.9x
Fixed Assets Turnover 28.9x
Days Sales Outstanding 68 days
Days Inventory 75 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Stemline Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Stemline Therapeutics, Inc.: With annual revenue of $47M, Stemline Therapeutics, Inc. represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $47M
Operating Income $-73M
Net Income $-71M
R&D Expense $96M
SG&A Expense $148M
Cost of Goods Sold $12M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 99%
Cash & Short-term Investments 89%
Total Liabilities 13%
Accounts Receivable 7%
Inventory 1%
Dividend & Shareholder Information
Shares Outstanding 45M

Latest Stemline Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Stemline Therapeutics, Inc. (STML) stock price and investment outlook.

Stemline Therapeutics, Inc. Competitors & Peer Analysis - Health Technology Sector

Comparative analysis of Stemline Therapeutics, Inc. against industry peers and competitors in the Health Technology sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio

Frequently Asked Questions - Stemline Therapeutics, Inc. Stock Forecast

How accurate are Stemline Therapeutics, Inc. stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for STML predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Stemline Therapeutics, Inc. stock price forecasts?

Our analysis considers Stemline Therapeutics, Inc.'s financial metrics, Health Technology sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Stemline Therapeutics, Inc. a good investment in 2025?

Based on our AI analysis, Stemline Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Stemline Therapeutics, Inc. forecasts updated?

Stemline Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Stemline Therapeutics, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Stemline Therapeutics, Inc. stock.

🎯 Get Premium Analysis 📊 Explore More Stocks

My Portfolio

Investment Dashboard

Loading your portfolio...